Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in Italy: The IMP-IT registry

Francesco Burzotta, Carlo Trani, Giovanni F Casucci, Alaide Chieffo, Marco B. Ancona, Vittorio Pazzanese, Carlo Briguori, Tommaso Piva, Federico De Marco, Maurizio Di Biasi, Paolo Pagnotta, Gavino Casu, Gennaro Giustino, Matteo Montorfano, Federico Pappalardo, Giuseppe Tarantini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)


Aims: The aim of this study was to investigate nationwide trends and clinical outcomes of the Impella device for cardiogenic shock (CS) and high-risk percutaneous coronary intervention (HR-PCI). Methods and results: The IMP-IT study was a multicentre observational national registry which enrolled all patients treated with Impella 2.5, Impella CP, Impella 5.0 and Impella RP, both for CS and HR-PCI indications, across 17 Italian centres from 2004 to June 2018. A total of 406 patients were included: 229 had CS (56.4%) and 177 underwent HR-PCI (43.6%). The use of Impella increased significantly during the study period (average annual percent change 39.8%, 95% confidence interval: 30.4 to 49.9; p<0.0001) for both indications. The Impella 2.5 was the most commonly used device (N=242; 59.6%). Rates of in-hospital and one-year all-cause death in patients with CS were 46.9% and 57.0%, respectively; 18.5% underwent left ventricular assist device implantation or heart transplant at one year. Rates of in-hospital and one-year allcause death in patients who underwent HR-PCI were 5.7% and 15.6%, respectively. Rates of device-related complications were 37.1% and 10.7% in the setting of CS and HR-PCI, respectively. Conclusions: Use of the Impella for CS and HR-PCI is increasing substantially in Italy, despite relatively high rates of device-related complications.
Lingua originaleEnglish
pagine (da-a)E1343-E1350
Stato di pubblicazionePubblicato - 2020


  • Acute heart failure
  • Cardiogenic shock
  • Heart-Assist Devices
  • Humans
  • Inosine Monophosphate
  • Italy
  • Left main
  • Multiple vessel disease
  • Percutaneous Coronary Intervention
  • Registries
  • Shock, Cardiogenic
  • Ventricular assist device

Fingerprint Entra nei temi di ricerca di 'Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in Italy: The IMP-IT registry'. Insieme formano una fingerprint unica.

Cita questo